RGEN Repligen Corporation featured news, full reports, and detailed charts
Repligen Corporation (RGEN) Wrap Up:
The following discussion of our business contains forward-looking statements that involve risks and uncertainties. When used in this report, the words “intend,” “anticipate,” “believe,” “estimate,” “plan” and “expect” and similar expressions as they relate to us are included to identify forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements and are a result of certain factors, including those set forth under “Risk Factors” and elsewhere in this Annual Report on Form 10-K. Repligen Corporation (“Repligen,” the “Company” or “we”) is developing novel therapeutics for the treatment of diseases of the central nervous system. We also own intellectual property on two biological therapies which may provide future revenues to support our product development efforts in neurological diseases. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2007%2f06%2f08%2f0001193125-07-132409.html#FIS_BUSINESS"www.repligen.com
69 Employees
Founded in 1981
Repligen Corporation (RGEN:NASDAQ)
LAST $4.76 USD
CHANGE TODAY +0.04 0.85%
VOLUME 46.7K
As of 4:00 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of Repligen Corporation (RGEN)
|
OPEN
$4.72
|
PREVIOUS CLOSE
$4.72
|
|
|
DAY HIGH
$4.82
|
DAY LOW
$4.72
|
|
|
52 WEEK HIGH
07/23/09 - $5.85
|
52 WEEK LOW
11/21/08 - $3.38
|
|
|
MARKET CAP
146.4M
|
AVERAGE VOLUME 3 mo
66.6K
|
|
|
DILUTED EPS TTM
$-0.16
|
SHARES OUTSTANDING
30.8M
|
|
|
RGEN Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
RGEN Top Compensated Officers
Dr. Walter C. Herlihy Ph.D.
Chief Executive Officer, President, Director ...
Age: 57
Total Annual Compensation: $365.0K
Mr. William J. Kelly CPA
Chief Financial Officer and Principal Account...
Age: 38
Total Annual Compensation: $190.0K
Dr. Daniel P. Witt Ph.D.
Vice President of Operations
Age: 62
Total Annual Compensation: $205.0K
Dr. James R. Rusche Ph.D.
Senior Vice President of Research & Developme...
Age: 55
Total Annual Compensation: $246.0K
Executives, Board Directors
Compensation as of Fiscal Year 2009.
Key developments for Repligen Corporation (RGEN)
Repligen Corporation Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended September 30, 2009
11/5/2009
Repligen Corporation reported unaudited earnings results for the second quarter and six months ended September 30, 2009. For the quarter, the company reported total revenue of $5,420,594, loss from operations of $1,206,391, loss before income taxes of $979,703 and net loss of $979,703 or $0.03 per diluted share compared with total revenue of $5,089,924, loss from operations of $324,518, income before income taxes of $191,601 and net income of $142,056 over the same period last year. For the six months, the company reported total revenue of $10,481,447, loss from operations of $2,634,114, loss before income taxes of $2,085,683 and net loss of $2,085,683 or $0.07 per diluted share compared with total revenue of $18,750,169, income from operations of $7,633,630, income before income taxes of $8,680,429 and net income of $8,420,884 or $0.27 per diluted share over the same period last year.
Repligen Corporation expected to Report Q3 2010 Results on February 1, 2010. This event was calculated by Capital IQ (Created on November 5, 2009).
11/5/2009
Repligen Corporation expected to Report Q3 2010 Results on February 1, 2010. This event was calculated by Capital IQ (Created on November 5, 2009).
Repligen Corporation Revised Earnings Guidance for the Fiscal Year 2010
11/5/2009
Repligen Corporation revised earnings guidance for the fiscal year 2010. The company reported that total revenue projection for fiscal year 2010 between $20 million and $22 million, including approximately $10 million in product sales, $10 million in royalty income and $1 million in other revenue. The company expects net loss to be between $7 million and $8 million, compared to earlier guidance of $5 million to $6 million.
RGEN Competitors
| Company | Last | Change |
| Bristol Myers Squibb Co | $24.46 USD | +0.43 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | RGEN | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 6.9x |
|
| Price/Book | 2.2x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 4.9x |
|
|
RGEN |
||
|
RGEN transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent News About Repligen Corporation
More news for RGEN
Repligen Announces Conference Call of Second Quarter Fiscal Year 2010 Results
WALTHAM, Mass., Oct. 29 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN - News) announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will host a conference call and webcast on Thursday, November 5th, 2009 at 10:00 a.m. EST, to report second quarter fiscal year 2010 financial results and to provide a quarterly update of the Company. This call is being webcast by Thomson/CCBN and can be accessed via Repligen's website at www.repligen.com. If you are unable to access the webcast via the internet, you may also listen to the live broadcast by calling (866) 804-6924 for domestic calls and (857) 350-1670 for international calls. Participants must provide the following passcode: 79134378. For those who cannot participate in the live conference call, an archive of the audio webcast will be available shortly after the call and may be accessed at www.repligen.com.About Repligen CorporationRepligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders. In additio...Click here to read the whole Article (external link)
Repligen Reports Second Quarter Fiscal Year 2010 Financial Results
WALTHAM, Mass., Nov. 5 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN - News) today reported results for the second quarter of fiscal year 2010, ended September 30, 2009. Total revenue for the quarter was $5,421,000 compared to total revenue of $5,090,000 for the second quarter of fiscal year 2009 ended September 30, 2008. Total revenue for the second quarter of fiscal year 2010 was comprised of Protein A product revenue of $2,742,000 and royalty and research revenue of $2,679,000, consisting primarily of royalty payments from Bristol-Myers Squibb on the U.S. sales of Orencia(®). Operating expenses for the second quarter of fiscal year 2010 were $6,627,000 compared to $5,414,000 for the same time period in fiscal year 2009. This increase in operating expenses of $1,213,000 was primarily the result of increased spending associated with our Phase 3 clinical trial of RG1068 for pancreatic imaging, our Phase 2b clinical trial of RG2417 for bipolar depression, and increased research and development costs associated with our efforts to identify a clinical candidate for Friedreich's ataxia. Selling, general and administrative expenses have also increased $359,000 due to expanded business development activities compared to the prior year.Net loss for the second quarter of fiscal year 2010 was $980,000 or $0.03 per diluted share, compared to a net gain for the second quarter of fiscal year 2009 of $142,000 or $0.00 per diluted share. Cash, cash equivalents and marketable securities as of September 30, 2009 were ...Click here to read the whole Article (external link)
Repligen to Present at the Merriman Curhan Ford 6th Annual Investor Summit Tuesday, November 10th, 1:40 p.m. EST
WALTHAM, Mass., Nov. 3 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN - News) announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will present at the Merriman Curhan Ford 6th Annual Investor Summit on Tuesday, November 10th, 2009 at 1:40 p.m. EST at the Sofitel New York Hotel, 45 West 44th Street, New York, New York. A live audio webcast of the presentation will be available via Repligen's website at www.repligen.com and will be archived for 30 days following the presentation. About Repligen CorporationRepligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for diseases that affect the central nervous system. In addition, we are the world's leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability. Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from www.repligen.com.This press release contains for...Click here to read the whole Article (external link)
Repligen Q2 Fiscal Year 2010 Earnings Release - Before Market Open
Earnings Announcements for Thursday, November 5CompanySymbolTimeConferenceCall21st Century HoldingTCHC2:00 pm ET3I INFRASTRUCTURE3IN.LBefore Market OpenAbiomed, Inc.ABMDBefore Market OpenListenABOVENET INCABVTAfter Market CloseListenAbraxis BioScience, Inc.ABIIBefore Market OpenListenAccelrys Inc.ACCLAfter Market CloseListenACI Worldwide, Inc.ACIWBefore Market OpenACTIONS SEMICONDUCTOR CO LTDACTSAfter Market CloseActive Biotech ABACTI.STTime Not SuppliedActivision Blizzard, Inc.ATVIAfter Market CloseAdecco SAAHEXF.PK01:00 am ETAinsworth Lumber Company Ltd.ANS.TOAfter Market CloseAir MethodsAIRMAfter Market CloseAker ASAAKERTime Not SuppliedALAMOS GOLD INCAGI.TOBefore Market OpenAlaska Communications Systems GroupALSKAfter Market CloseAlexandria Real Estate...Click here to read the whole Article (external link)
Repligen Corp. F2Q09 (Qtr. End 09/30/09) Earnings Call Transcript
Repligen Corp. (RGEN) F2Q09 (Qtr. End 09/30/09) Earnings Call November 05, 2009 10:00 a.m. ET Executives William Kelly - CFO Walter Herlihy - President and CEO Analysts Joe Pantginis - Merriman Curhan Michael Panaro - MDP Associates Presentation Operator Good day ladies and gentlemen and welcome to the Repligen second quarter fiscal year 2010 earnings conference call. My name is Michelle and I’ll be your coordinator for today. At this time all participants are in a listen-only mode. We will be facilitating a question and answer session towards the end of today’s conference. (Operator Instructions). I would now like to turn the presentation over to your host for today’s call Mr. William Kelly, Chief Financial Officer. Please proceed sir. William Kelly Thank you and good morning. The purpose of today’s call is to briefly review our financial results for Q2 of our fiscal year 2010. Update our financial projections for the year, and to update the status of our development programs. Joining me today is Walter Herlihy our President and CEO. At the outset, I would like to state that this discussion will contain forward-looking statements, which are not guarantees of future performance, such as our financial projections and projections for the U.S. sales of Orencia®, opportunities for licensing. Our intellectual property portfolio and our plans and projections for clinical trials. These statements are subject to certain factors, which may cause Repligen’s plans to materially differ or results to materially vary from those expected, including...Click here to read the whole Article (external link)
Repligen Q2 Fiscal Year 2010 Earnings Call scheduled for 10:00 am ET today
Call DetailsRepligen Q2 Fiscal Year 2010 Earnings Conference CallThu, Nov 5, 2009, 10:00 am EasternAbout Repligen Corporation (NasdaqGM:RGEN)Other Calls Repligen Corporation develops novel therapeutics primarily for the treatment of diseases of the central nervous system. The company offers Protein A products, which are used in the production and purification of therapeutic monoclonal antibodies. Repligen also licenses its patent covering the use of CTLA4-Ig, a regulator of the activity of the immune system, and receives royalties from Bristol-Myers Squibb based on their U.S. Sales of Orencia. The company’s development stage products include RG1068, human secretin for improved MRI of the pancreas; RG2417, uridine for bipolar depression; HDAC inhibitors for Friedreich’s ataxia; and RG-SMA for spinal muscular atrophy. The company sells its Protein A products primarily through value-added resellers, as well as through distributors internationally. Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts.More Info:Quote |Chart |News |Profile |Reports |Research |SEC |Msgs |Insider |Financials | Analyst Ratings...Click here to read the whole Article (external link)
REPLIGEN CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
Show all filings for REPLIGEN CORP | Request a Trial to NEW EDGAR Online Pro Form 8-K for REPLIGEN CORP 5-Nov-2009Results of Operations and Financial Condition, Financial Statements and Exhibits Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is"...Click here to read the whole Article (external link)
New Star Analyst Rankings for Repligen Corporation
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Copyright © 1999-2003, StarMine Corp. All rights reserved.StarMine Corp. derives analyst ratings from estimate and recommendation data supplied by Thomson Financial.Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). International historical chart data, daily updates, fund summary, fund performance, dividend data and...Click here to read the whole Article (external link)
REPLIGEN CORP Financials
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...Click here to read the whole Article (external link)
Would you like to leave a comment about Repligen Corporation RGEN
Find out what social network information about Repligen Corporation are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Repligen Corporation there is more great information available at Realpennies.com